Birth tissue material and method of preparation

1. A method of treating a soft tissue defect in or on the body of a patient comprising the steps of:

providing a placental construct comprising: i) a therapeutically effective amount of a human birth tissue material that is cryofrozen, morselized and subsequently suspended in a tissue suspension solution; and ii) an amniotic fluid composition; and

administering the placental construct directly into or onto the soft tissue defect,

wherein the tissue suspension solution comprises about 36% volume of human albumin 25% solution and about 20% volume of dimethyl sulfoxide.

2. The method of claim 1 , wherein the soft tissue defect is a diabetic ulcer, decubitus ulcer, venous leg ulcer, arterial leg ulcer, cutaneous ulcer, or a combination thereof.

3. The method of claim 1 , wherein the construct further comprises one or more structural carriers selected from the group consisting of an amniotic membrane and/or chorionic membrane, a soft tissue allograft, a bone allograft, and platelet rich plasma.

4. The method of claim 1 , wherein the construct is administered in combination with one or more bioactive agents selected from the group consisting of physiologically compatible minerals, growth factors, antibiotics, chemotherapeutic agents, antigens, antibodies, enzymes, vectors for gene delivery, and hormones.

5. A method of treating a soft tissue defect in or on the body of a patient comprising the step of

administering a placental construct directly into or onto the soft tissue defect, wherein the placental construct comprises a therapeutically effective amount of a human birth tissue material comprising a tissue suspension and an amniotic fluid composition, the human birth tissue material prepared according to a process comprising the steps of:

(a) recovering placental tissue components and amniotic fluid from a single seronegative, healthy human via cesarean section or vaginal delivery;

(b) subjecting the placental tissue components to cryopreservation;

(c) morselizing the cryopreserved placental tissue components;

(d) homogenizing the morselized placental tissue components in a tissue suspension solution to form a tissue suspension;

(e) centrifuging the amniotic fluid from step (a) to form a pellet that is retained and a supernatant that is aspired off;

(f) suspending the pellet in a cell suspension solution to form an amniotic fluid composition;

(g) homogenizing the tissue suspension from step (d) with the amniotic fluid composition of step (f) to form a bulk tissue product; and

(h) cryofreezing the bulk tissue product to form the human birth tissue material;

wherein the tissue suspension solution comprises about 36% volume of human albumin 25% solution and about 20% volume of dimethyl sulfoxide.

6. The method of claim 5 , wherein the soft tissue defect is a diabetic ulcer, decubitus ulcer, venous leg ulcer, arterial leg ulcer, cutaneous ulcer, or a combination thereof.

7. The method of claim 5 , wherein the construct further comprises one or more structural carriers selected from the group consisting of an amniotic membrane and/or chorionic membrane, a soft tissue allograft, a bone allograft, and platelet rich plasma.

8. The method of claim 5 , wherein the construct is administered in combination with one or more bioactive agents selected from the group consisting of physiologically compatible minerals, growth factors, antibiotics, chemotherapeutic agents, antigens, antibodies, enzymes, vectors for gene delivery, and hormones.